Drug Maker KaloBios Touts Fair Pricing

[wsj-responsive-image P="http://si.wsj.net/public/resources/images/BN-NE663_KALOBI_P_20160321173206.jpg" J="http://si.wsj.net/public/resources/images/BN-NE663_KALOBI_J_20160321173206.jpg" M="http://si.wsj.net/public/resources/images/BN-NE663_KALOBI_M_20160321173206.jpg" caption="Martin Shkreli, the former CEO of KaloBios who was ousted last year following his arrest on unrelated securities-fraud charges" credit=John Taggart/European Pressphoto Agency" placement="Inline" suppressEnlarge="false" ]

Drug maker KaloBios Pharmaceuticals is touting a new policy that calls for charging cost plus “reasonable and transparent profit margin.” The Wall Street Journal has the Daily Bankruptcy Review article here. The company’s new chief executive, who took over after Martin Shkreli was ousted last year, wants to “set the record straight” about a no-gouging policy.

(Daily Bankruptcy Review is a daily newsletter with comprehensive coverage and analysis of emerging and in-progress insolvencies and turnarounds. For a two-week trial, visit http://on.wsj.com/DJBankruptcyNews, scroll to the bottom and click “try for free.”)

Former AnchorBank executive David Weimert was released from prison after being acquitted of wire fraud, DBR reports in WSJ.

DealBook reports on Puerto Rico’s new debt-reduction plan, which was filed Monday.

Big banks will announce earnings Wednesday. The spotlight? Energy loans, which are turning into a headache, WSJ reports.

“Too big to fail” might be tough for a generalist to judge, DealBook reports.

(And don’t forget to check out the latest bankruptcy professional moves.)

Write to Melanie Cohen at [email protected]. Follow her on Twitter at @MelanieLisa